We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Bladder Cancer

Journal Scan / Research · September 23, 2020

Cost-Effectiveness of Pembrolizumab Versus Carboplatin-Based Chemotherapy as 1L Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-Based Therapy in the US

Clinical Genitourinary Cancer

 

Additional Info

Clinical Genitourinary Cancer
Cost-Effectiveness of Pembrolizumab Versus Carboplatin-Based Chemotherapy as First-line Treatment of PD-L1-Positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-Based Therapy in the United States
Clin Genitourin Cancer 2020 Jul 16;[EPub Ahead of Print], O Hale, K Patterson, Y Lai, Y Meng, H Li, JL Godwin, B Homet Moreno, R Mamtani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading